Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)

H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--October 6, 2014--BioTime, Inc. (NYSE

MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are

joining its Board of Directors. Mr. Mulroy has been appointed to the

Board to fill a vacancy and Mr. Cartt has been nominated for election to

the Board at the Company's upcoming annual shareholders' meeting, which

will be held on November 4.

Mr. Mulroy most recently served as Executive Vice President - Strategic

Affairs and General Counsel of the Autoimmune and Rare Diseases Business

Unit of Mallinckrodt plc. This transitional role followed Mallinckrodt's

acquisition of Questcor Pharmaceuticals for $5.8 billion in August 2014.

At Questcor, Mr. Mulroy served in various capacities during his tenure

from January 2011 to September 2014, including as Executive Vice

President - Strategic Affairs, Chief Financial Officer, General Counsel,

and Corporate Secretary. During the time Mr. Mulroy worked at Questcor,

the company's stock price rose more than 500%. Prior to Questcor, Mr.

Mulroy was a partner at the law firm of Stradling Yocca Carlson & Rauth,

before which he was an investment banker at Merrill Lynch and Citigroup.

He earned his J.D. degree from the University of California, Los Angeles

and his B.A. (Economics) from the University of Chicago.

Mr. Cartt has most recently served in a transitional role as Chief

Operating Officer of the Autoimmune and Rare Diseases Business Unit of

Mallinckrodt following its acquisition of Questcor, where he served as

Chief Operating Officer. Mr. Cartt worked at Questcor for more than nine

years and played a major role in the company's success. During that

time, Questcor's stock price rose more than 200-fold. Prior to his

appointment to the position of Chief Operating Officer in February 2012,

Mr. Cartt served as Executive Vice President and Chief Business Officer.

Prior to working at Questcor, he was the Senior Director of Strategic

Marketing for Elan Pharmaceuticals and previously held a variety of R&D

and Commercial positions at ALZA Corporation. Mr. Cartt holds a B.S.

degree in biochemistry from the University of California at Davis and an

M.B.A. from Santa Clara University.

"We are very pleased that Mike Mulroy and Steve Cartt are joining our

Board of Directors," commented Michael D. West, BioTime's Chief

Executive Officer. "Both of these executives have exceptional track

records of creating substantial shareholder value over time, most

recently at Questcor, where they were instrumental in successfully

managing a period of rapid growth, commercial expansion, and increased

investment in research and development. As BioTime and its subsidiaries

move into clinical trials with several products, we are focused on

adding biopharmaceutical industry executives to our management teams and

boards of directors who have records of successfully advancing products

through clinical trials and commercialization while creating substantial

"Steve and Mike have valuable experience with the investment community,

with clinical and commercial stage products, and with financing public

companies with breakthrough technologies," Dr. West continued. "As

BioTime's subsidiaries progress further, that experience is likely to be

particularly valuable. For example, Asterias recently became the first

of BioTime's subsidiaries to be publicly traded. When Steve joined

Questcor, it was considerably smaller than BioTime is today, and when

Mike joined Questcor, it was only moderately larger than BioTime is

today. We look forward to working closely with both Mike and Steve to

build significant value for BioTime's shareholders over time."

BioTime is a biotechnology company engaged in research and product

development in the field of regenerative medicine. Regenerative medicine

refers to therapies based on stem cell technology that are designed to

rebuild cell and tissue function lost due to degenerative disease or

injury. BioTime's focus is on pluripotent stem cell technology based on

human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")

cells. hES and iPS cells provide a means of manufacturing every cell

type in the human body and therefore show considerable promise for the

development of a number of new therapeutic products. BioTime's

therapeutic and research products include a wide array of proprietary PureStem

progenitors, HyStem hydrogels, culture media,

and differentiation kits. BioTime is developing Renevia (a HyStem

product) as a biocompatible, implantable hyaluronan and collagen-based

matrix for cell delivery in human clinical applications, and is planning

to initiate a pivotal clinical trial around Renevia , in 2014. In

addition, BioTime has developed Hextend , a blood

plasma volume expander for use in surgery, emergency trauma treatment

and other applications. Hextend is manufactured

and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ

HealthCare Corporation, under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research,

therapeutic, and diagnostic use through its subsidiaries:

Asterias Biotherapeutics, Inc. (OTCBB: ASTY) is developing

pluripotent stem-cell based therapies in neurology and oncology,

including AST-OPC1 oligodendrocyte progenitor cells in spinal cord

injury, multiple sclerosis and stroke, and AST-VAC2, an allogeneic

dendritic cell-based cancer vaccine. Asterias trades publicly under

BioTime Asia, Ltd., a Hong Kong company, may offer and sell

products for research use for BioTime's ESI BIO Division.

Cell Cure Neurosciences Ltd. is an Israel-based biotechnology

company focused on developing stem cell-based therapies for retinal

and neurological disorders, including the development of retinal

pigment epithelial cells for the treatment of macular degeneration,

and treatments for multiple sclerosis.

ESI BIO is the research and product marketing division of

BioTime, providing stem cell researchers with products and

technologies to enable them to translate their work into the clinic,

including PureStem progenitors and HyStem

LifeMap Sciences, Inc. markets, sells, and distributes GeneCards ,

the leading human gene database, as part of an integrated database

suite that also includes the LifeMap Discovery

database of embryonic development, stem cell research, and

regenerative medicine, and MalaCards, the human disease

LifeMap Solutions, Inc. is a subsidiary of LifeMap Sciences

focused on developing mobile health (mHealth) products.

OncoCyte Corporation is developing products and technologies to